Infiltration of immune cells to the brain and its relation to the pathogenesis of Alzheimer's and Parkinson's diseases

被引:4
|
作者
Netzahualcoyotzi, Citlalli [1 ,2 ,5 ]
Santillan-Cigales, Juan Jair [1 ]
Adalid-Peralta, Laura Virginia [2 ]
Velasco, Ivan [1 ,2 ,3 ,4 ]
机构
[1] Univ Nacl Autonoma Mexico, Inst Fisiol Celular Neurociencias, Mexico City, Mexico
[2] Inst Nacl Neurol & Neurocirugia Manuel Velasco Sua, Lab Reprogramac Celular, Mexico City, Mexico
[3] Univ Nacl Autonoma Mexico, Inst Fisiol Celular Neurociencias, Mexico City 04510, Mexico
[4] Inst Nacl Neurol & Neurocirugia Manuel Velasco Sua, Lab Reprogramac Celular, Mexico City 14269, Mexico
[5] Ctr Invest & Estudios Avanzados CINVESTAV, Dept Farmacol, Mexico City, Mexico
关键词
Alzheimer's disease; blood-brain barrier; leukocytes; neuroimmunology; neurovascular unit; Parkinson's disease; CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA-PROTEIN; CD8; T-CELLS; ALZHEIMERS-DISEASE; MAST-CELLS; MOUSE MODEL; IFN-GAMMA; BARRIER PERMEABILITY; NEUROVASCULAR UNIT; MICROGLIAL ACTIVATION;
D O I
10.1111/jnc.16106
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The neurovascular unit, composed of vascular endothelium, vascular smooth muscle, extracellular matrix components, pericytes, astrocytes, microglia, and neurons, allows the highly regulated exchange of molecules and the limited trafficking of cells to the brain through coordinated signaling activity. The passage of peripheral immune cells to the brain parenchyma is observed when there is clear damage to the barriers of this neurovascular unit, as occurs in traumatic brain injury. The possibility of leukocyte infiltration to the brain in neurodegenerative conditions has been proposed. In this review, we focus on describing the evidence for peripheral immune cell infiltration to the brain in the two most frequent neurodegenerative diseases: Alzheimer's and Parkinson's diseases. In particular, we address the mechanisms that promote the passage of these cells into the brain under such pathological conditions. We also discuss the relevance of the resulting cellular interactions, which provide evidence that the presence of peripheral immune cells in the brain is a key point in these neurodegenerative diseases. The disruption of the neurovascular unit and the infiltration of the peripheral immune cells into the central nervous system are hallmarks of neurodegenerative diseases. However, so far, the participation of infiltrating cells in the progression of these diseases has not been completely defined. In this work, we gather the evidence that exists until now which proposes the key events involved in the pathogenesis of the two main neurodegenerative diseases: Alzheimer's and Parkinson's diseases. We detail the alterations in the components that typically keep the neurovascular unit semi-permeable to the cellular interactions that promote a self-perpetuating cycle of inflammation.image
引用
收藏
页码:2316 / 2334
页数:19
相关论文
共 50 条
  • [21] Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review
    Mangone, Graziella
    Tosin, Michelle H. S.
    Goetz, Christopher G.
    Stebbins, Glenn T.
    Mestre, Tiago A.
    MOVEMENT DISORDERS, 2024, 39 (03) : 560 - 570
  • [22] Parkinson's disease and vitamins: a focus on vitamin B12
    Rekik, Arwa
    Santoro, Carlo
    Poplawska-Domaszewicz, Karolina
    Qamar, Mubasher Ahmad
    Batzu, Lucia
    Landolfo, Salvatore
    Rota, Silvia
    Falup-Pecurariu, Cristian
    Murasan, Iulia
    Chaudhuri, Kallol Ray
    JOURNAL OF NEURAL TRANSMISSION, 2024, 131 (12) : 1495 - 1509
  • [23] Exploring the significance of lipids in Alzheimer's disease and the potential of extracellular vesicles
    Su, Huaqi
    Masters, Colin L.
    Bush, Ashley I.
    Barnham, Kevin J.
    Reid, Gavin E.
    Vella, Laura J.
    PROTEOMICS, 2023,
  • [24] The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (leads) Cohort
    Touroutoglou, Alexandra
    Katsumi, Yuta
    Brickhouse, Michael
    Zaitsev, Alexander
    Eckbo, Ryan
    Aisen, Paul
    Beckett, Laurel
    Dage, Jeffrey L.
    Eloyan, Ani
    Foroud, Tatiana
    Ghetti, Bernardino
    Griffin, Percy
    Hammers, Dustin
    Jack, Clifford R.
    Kramer, Joel H.
    Iaccarino, Leonardo
    La Joie, Renaud
    Mundada, Nidhi S.
    Koeppe, Robert
    Kukull, Walter A.
    Murray, Melissa E.
    Nudelman, Kelly
    Polsinelli, Angelina J.
    Rumbaugh, Malia
    Soleimani-Meigooni, David N.
    Toga, Arthur
    Vemuri, Prashanthi
    Atri, Alireza
    Day, Gregory S.
    Duara, Ranjan
    Graff-Radford, Neill R.
    Honig, Lawrence S.
    Jones, David T.
    Masdeu, Joseph C.
    Mendez, Mario F.
    Musiek, Erik
    Onyike, Chiadi U.
    Riddle, Meghan
    Rogalski, Emily
    Salloway, Stephen
    Sha, Sharon
    Turner, R. Scott
    Wingo, Thomas S.
    Wolk, David A.
    Womack, Kyle
    Carrillo, Maria C.
    Rabinovici, Gil D.
    Apostolova, Liana G.
    Dickerson, Bradford C.
    ALZHEIMERS & DEMENTIA, 2023, 19 : S74 - S88
  • [25] Istradefylline/L-DOPA Parkinson's disease therapy and energy coupling
    Kanzato, Naomi
    Nakachi, Koh
    Mochizuki, Satsuki
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2024, 12 (05): : 296 - 305
  • [26] Day-to-day sleep variability with Alzheimer's biomarkers in at-risk elderly
    Baril, Andree-Ann
    Picard, Cynthia
    Labonte, Anne
    Sanchez, Erlan
    Duclos, Catherine
    Mohammediyan, Bery
    Ashton, Nicholas J.
    Zetterberg, Henrik
    Blennow, Kaj
    Breitner, John C. S.
    Villeneuve, Sylvia
    Poirier, Judes
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2024, 16 (01)
  • [27] Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation
    Dorsey, E. Ray
    Kinel, Dan
    Pawlik, Meghan E.
    Zafar, Maryam
    Lettenberger, Samantha E.
    Coffey, Madeleine
    Auinger, Peggy
    Hylton, Kevin L.
    Shaw, Carol W.
    Adams, Jamie L.
    Barbano, Richard
    Braun, Melanie K.
    Schwarz, Heidi B.
    Lawrence, B. Paige
    Kieburtz, Karl
    Tanner, Caroline M.
    de Miranda, Briana R.
    Goldman, Samuel M.
    MOVEMENT DISORDERS, 2024, 39 (03) : 606 - 613
  • [28] Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial
    Molina-Henry, Doris Patricia
    Raman, Rema
    Liu, Andy
    Langford, Oliver
    Johnson, Keith
    Shum, Leona K.
    Glover, Crystal M.
    Dhadda, Shobha
    Irizarry, Michael
    Jimenez-Maggiora, Gustavo
    Braunstein, Joel B.
    Yarasheski, Kevin
    Venkatesh, Venky
    West, Tim
    Verghese, Philip B.
    Rissman, Robert A.
    Aisen, Paul
    Grill, Joshua D.
    Sperling, Reisa A.
    ALZHEIMERS & DEMENTIA, 2024, 20 (06) : 3827 - 3838
  • [29] The therapeutic value of thiazole and thiazolidine derivatives in Alzheimer's disease: a systematic literature review
    Abdollahi, Zahra
    Nejabat, Mojgan
    Abnous, Khalil
    Hadizadeh, Farzin
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2024, 19 (01) : 1 - 12
  • [30] Yeast Prion Protein Sup35 Initiates α-Synuclein Pathology in Parkinson's Disease
    Wang, Youcui
    Li, Hui
    Song, Ning
    Xie, Junxia
    MOVEMENT DISORDERS, 2024, 39 (05) : 766 - 767